Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
Cristiane Bergerot PhD, MS, BS, a health psychologist at the City of Hope National Medical Center, discusses how a higher starting dose of lenvatinib (Lenvima), to be combined with everolimus (Afinitor), can improve health-related quality of life (HRQoL) in patients with renal cell carcinoma (RCC), as demonstrated in a phase 2 open-label trial.
Results from the trial, presented during the 2021 Genitourinary Cancers Symposium, revealed that favorable clinical outcomes could be achieved with an 18-mg starting dose of lenvatinib, Bergerot says. Notably, findings indicate that when the agent was given at this dose, patients experienced better HRQoL and fewer disease-related symptoms, Bergerot explains.
Additionally, those who received the higher starting dose had less disease burden and better clinical outcomes compared with those who received the 14-mg dose of the agent; this is indicative of an overall efficacy that is clinically meaningful, Bergerot concludes.